Physiology of an Erection
A penile erection is a transformation of penile tissue and vasculature from a state of minimally perfused flaccidity into an engorged state. Prelox ® for Improvement of Erectile Quality The amino acid L-arginine plays a key role in vasculature dynamics because it represents the substrate for all NOS isoforms. Arginine supplementation is able to increase NO production despite physiological concentrations exceeding saturation levels of NOS, a phenomenon known as the 'arginine paradox'. 5 In patients with diagnosed ED, dietary supplementation with L-arginine alone appears to be effective for improving the condition, provided the dosage and intake duration are sufficient. One group in a double-blind, placebocontrolled trial found significant improvements with 5g L-arginine per day over a period of six weeks. 6 Another group found in a double-blind, placebo-controlled, cross-over study that 1.5g L-arginine a day for 17 days was ineffective. 7 Experiments with isolated human corpus cavernosum leave little doubt that L-arginine evokes detectable corpus cavernosum relaxation proportional to concentration and time. 8 Pycnogenol consists of phenolic substances chemically classified as flavonoids: phenolic acids resembling benzoic acid and cinnamic acid derivatives, taxifolin and procyanidins, condensed catechin and epicatechin moieties of variable chain length (n=2-12). 9 Pycnogenol is standardized to contain 65±5% procyanidins, as detailed in the United States Pharmacopoeia. Another double-blind, placebo-controlled Prelox product evaluation study was carried out in 124 men (average age 44 years) presenting with moderate ED. 21 Men in stable partnerships for at least six months presenting with moderate ED were enrolled. Patients were randomly assigned to either four Prelox tablets (two in the morning, two in the evening) or corresponding placebo tablets over a period of six months.
Fasting blood samples were taken at baseline and following completion of the trial for standard blood chemistry and rheology.
Thirteen men dropped out due to non-medical reasons. In the Prelox group, the average IIEF score increased from a baseline of 15±6.6 to 25±2 after six months of treatment. The placebo group started with an Prelox ® for Improvement of Erectile Quality
average score of 15±7, which increased to 19±3 at trial end. The improved erectile quality in the Prelox group was statistically significant compared with the placebo group (p<0.05) (see Figure 2 ).
More men in the Prelox group than in the control group reported increased morning erections (36 versus 12%), easier to initiate erections (38 versus 12%), partner noticing increased interest (38 versus 6%) and partner noticing improved performance (38 versus 12%). Many men were uneasy about responding to the above questions.
Blood chemistry and rheology found no major changes after six months of Prelox or placebo intake. A non-significant decrease of systolic blood pressure from a baseline average of 138.9 to 131.0mmHg was found in the Prelox group. A statistically significant increase of plasma testosterone was evident in the Prelox group, from a baseline of 458 to 544ng/dl after six months, representing an increase of 18.8%.
Duration of Action
In principle, the activity of Prelox is directed towards restoring endothelial function, which will allow men to spontaneously respond to sexual arousal. How quickly a man experiences an improvement of erectile quality will depend on his individual situation. From the clinical trial of Stanislavov et al., information is available on the earliest effects of erectile quality. 14 This was reported to be as early as one day after taking four Prelox tablets, with the latest response reportedly after nine days; the mean response occurred after 4.9 days. This trial also showed that following discontinuation of Prelox for one month, erectile quality decreases to almost pre-treatment levels.
An important point to consider is whether a habituation effect may occur after continuous supplementation with Prelox, with the effect on erectile quality gradually fading with time. The study by Ledda et al.
provides information that this does not occur; in fact, the contrary is true. 21 A comparison of IIEF scores after three months on Prelox with scores after six months clearly shows that erectile quality further improves following an additional three months of treatment. Therefore, in order to achieve the best effects Prelox would need to be taken continuously, without interruption.
Dosing and Absorption
In all clinical investigations for improvement of erectile quality, a daily dosage of four Prelox tablets was taken. In one study the equivalent of six Prelox tablets was taken for one month. The ideal initial dosage would thus be four Prelox tablets a day: two in the morning after breakfast and another two after dinner. Once erectile quality has sufficiently improved, the dosage may be adjusted to a maintenance dosage, which could be three or two Prelox tablets a day. The suitable maintenance dose will depend on a man's individual condition.
Metabolism and Excretion
Dietary L-arginine is absorbed in the small intestine via a specific amino acid transport system. About 60% of the absorbed L-arginine is metabolised by gastrointestinal enterocytes, while only 40% reaches the systemic circulation intact. 5 The average dietary consumption of L-arginine is about 5g/day. L-arginine undergoes various metabolic fates:
much is converted to NO and L-citrulline, the latter being largely converted in the proximal renal tubule to L-arginine. Furthermore, L-arginine may be utilised for protein synthesis or converted into other amino acids such L-ornithine, L-proline and L-glutamate. L-arginine is an alkaline amino acid that is not very water-soluble, unless in ionic forms with anionic countercharge; aspartate fulfils this purpose in Prelox.
The pharmacokinetics and excretion of Pycnogenol were shown to be of complicated nature in humans. The smaller flavonoid constituents, namely the phenolic acids and catechin, are found in blood plasma of humans within 30 minutes after oral consumption. 22 These constituents are excreted in the urine as sulphates and glucuronates, with peak times about two hours post-consumption. 23 The procyanidins are metabolised in the colon prior to absorption into the blood stream.
Specifically, the metabolite δ-(3,4-diydroxy-phenyl)-γ-valerolactone was identified in the plasma beginning four hours after consumption, and appears in the urine at peak eight to 10 hours post-consumption.
Several further metabolites can be found in the plasma of humans that have so far not been identified in the urine.
Adverse Effects
In all four clinical trials Prelox was well tolerated and no side effects 
Safety and Drug Interactions
Pycnogenol acute oral toxicity is very low, with a demonstrated no observed adverse effect level (NOAEL) of 150mg/kg. 9 Pycnogenol itself is known to cause stomach discomfort in some particularly sensitive people because of the pronounced astringency of the procyanidins. This happens only when Pycnogenol is taken on an empty stomach. Interestingly, stomach discomfort has not been reported for Prelox. A possible explanation is that the considerable amount of amino acids helps to avoid the stomach discomfort.
There is some dispute as to possible harm from L-arginine in people suffering from herpes. As early as the 1960s it was found that L-arginine promotes replication of herpes simplex in tissue culture, while L-lysin inhibits replication. The authors concluded: "the in vitro data may be the basis for the observation that patients prone to herpetic lesions and other related viral infections, particularly during periods of stress, should abstain from arginine excess and may also require supplemental lysine in their diet". 24 Whereas L-lysin indeed appears to offer prophylactic activity for managing recurrent herpes outbreaks in humans, 25 more recent studies suggest that L-arginine has antiviral effects against herpes simplex.
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A further unsubstantiated possible side effect of L-arginine is the promotion of tumour growth. One group has described higher protein synthesis in breast tumours as a result of supplementation with L-arginine. 27 The same group later argued that dietary supplementation with L-arginine would offer adjuvant treatment for improved host defence in breast cancer patients as a result of immunostimulatory effects. 28 The work of this group has left Erectile Dysfunction 74 considerable confusion, with various publications on L-arginine in cancer patients with contradictory findings.
However, men who have suffered a myocardial infarction should definitely refrain from taking Prelox because L-arginine may pose a health risk to them. 29 One study investigated supplementation with accelerating dosages of L-arginine, from 3 to 9g daily, for improving vascular stiffness and heart ejection fraction in addition to standard post-infarction therapy. The study was prematurely terminated after six months because of safety concerns, as six patients (8.6%) taking L-arginine died, whereas none in the placebo group did. Interestingly, after six months the L-arginine plasma levels were not significantly different between the treatment and placebo groups. The authors state "the excess mortality was an unexpected safety monitoring concern and the results could be due to (small but nonzero) chance". 
